ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      96,801.09
      -0.98%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Anavex Life Sciences Corporation (AVXL)

      7. Anavex Life Sciences Corporation (AVXL) News

      Anavex Life Sciences Corporation

      Anavex Life Sciences Corporation (AVXL)

      NASDAQ
      8.63
      0.16
      (1.89%)
      Closed December 21 4:00PM
      Delayed by 15 minutes
      8.5008
      -0.1292
      (-1.50%)
      After Hours: 7:55PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      AVXL News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 06 2024
      AVXL (1.89%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 06 2024
      AVXL (1.89%)

      AVXL Discussion

      View Posts
      hnbadger1 hnbadger1 2 hours ago
      The abstract of the patent application titled
      "Therapy Selection and Treatment of Neurodegenerative Disorders" describes a method for individualized therapy selection and monitoring for neurodegenerative disorders. The focus is on using Sigma-1 receptor agonist therapy to treat neurodegenerative diseases. The therapy is tailored based on gene expression analysis before and after treatment, enabling a personalized approach.
      Additionally, the disclosure includes tools for assessing the current status or risk of a subject for developing such disorders. These tools are organized as kits that assist in implementing the described methods.

      The provided document outlines the components of the kit for individualized therapy selection and monitoring for neurodegenerative disorders.
      Kit Components:
      1. Biological Sample Collection Materials:
      • Tools for collecting biological samples, such as blood, saliva, or tissue, for analysis of gene expression.
      2. Diagnostic Assays:
      • Tests designed to identify biomarkers indicative of neurodegenerative disorders.
      • Likely includes reagents, substrates, and controls for reliable measurement.
      3. Sigma-1 Receptor Agonist:
      • The therapeutic agent used in the treatment, specifically targeting Sigma-1 receptors.
      • May be provided in pre-measured doses tailored to individual therapy.
      4. Gene Expression Analysis Tools:
      • Equipment and reagents for analyzing gene expression pre- and post-treatment.
      • Could include tools for RNA sequencing or other genomic technologies.
      5. Data Processing Software:
      • Programs or access to cloud-based tools for interpreting genetic data.
      • Algorithms to recommend individualized treatment plans based on gene expression changes.
      6. Instructional Documentation:
      • Guidelines for using the kit, including sample collection, therapy administration, and result interpretation.
      • Step-by-step protocols to ensure consistency and reliability.
      7. Risk Assessment Tools:
      • Instruments or methodologies to evaluate the subject's current risk of developing neurodegenerative disorders.
      • May include scoring systems or diagnostic algorithms.
      Purpose and Utility
      The kit is intended to:
      • Provide a comprehensive platform for personalized diagnosis and therapy.
      • Enable clinicians to monitor treatment effectiveness through pre-and post-treatment biomarkers.
      • Facilitate early detection and preventive measures for neurodegenerative diseases.
      Thanks 45bulls on stock twits!
      🎯 1 👍️ 3
      hnbadger1 hnbadger1 3 hours ago
      It seems like Anavex has built a proprietary software and diagnostic toolkit for CNS diseases using blarcamesine. They give a patient drug and measure before/after genetic response. They can then diagnose or determine risk for developing CNS diseases.
      PERSONALIZED MEDICINE for most CNS diseases. Congrats to all longs, don't sell anytime soon P
      ppubs.uspto.gov/dirsearch-p...
      🎯 1 👍️ 4
      Steady_T Steady_T 6 hours ago
      That 2,347,246 looks to be the total vol for the trading day excluding AH trades.

      I show total vol including AH trades as 2,514,195.
      👍️ 2
      Investor2014 Investor2014 7 hours ago
      This patent application filed 23.11.2022 concerns the findings from below poster presentation at AAIC October 9-12, 2022.

      Those dates is a bit of an issues as the invention was disclosed at AAIC before the patent filing date.

      It is yet another way to patch up the IP protection of A2-73 standalone originally patented by Vamvakides and now expired.

      👎️ 1 👺 1
      georgejjl georgejjl 7 hours ago
      US20240417798 - THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS

      https://patentscope.wipo.int/search/en/detail.jsf?docId=US444400063&_cid=P10-M4XSG4-93338-1

      Good luck and GOD bless and have a very merry CHRISTmas.
      👍 3
      rx7171 rx7171 7 hours ago
      “In press”
      The publication is announcing the article has been reviewed and is accepted for publication.
      🎯 2 👍️ 3
      ignatiusrielly35 ignatiusrielly35 8 hours ago
      As I advised last week, there was zero chance that the imaginary mm manipulators would allow the call options at $9 and above to be ITM. 

      There are no more weeklies, for whatever reason, so you have another month.
      👍️ 2 😃 1
      georgejjl georgejjl 11 hours ago
      A MUST READ A brand new US Patent Application

      https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20240417798?requestToken=eyJzdWIiOiI4OGY5NWYxZS1hZTRkLTQ3YzUtYWRjOS01ZDgwZDNhMzE5NGEiLCJ2ZXIiOiI2YTgwZWM2YS1kYjA1LTQ1MzYtODJlZi02M2IxZGU2NjhkZDEiLCJleHAiOjB9

      Good luck and GOD bless,
      👋 1 👍️ 7 😃 1 ✈️ 1
      kund kund 11 hours ago
      Triple witching day, nothing special about this POS.
      👎️ 1 👺 1 🧻 1
      k9uwa k9uwa 11 hours ago
      Notice the MOC today 1,226,230 shares. Yes we see 60K, 100K, 160K for MOC order is not unusual. But 1,226,230 is a serious buy. Probably took all day for the MM's to bag up enough shares to cover that buy. And then later in after hours almost 19:00 2,347,246 share trade.
      Click the link below and then slide across and watch the Volume By the Minute.
      https://www.cnbc.com/quotes/AVXL?qsearchterm=
      John k9uwa
      🎯 1 👍️ 9
      bb8675309 bb8675309 11 hours ago
      Just ask Kund. He'll tell you. He was a huge SAVA supporter.
      😆 2
      bb8675309 bb8675309 11 hours ago
      I agree. Sava would be at $250.00 per share right now if it had the same results as Anavex to date.. Around a $20 Billion MC. Motley Fool would have them as a Strong Buy.
      👍️ 3 😂 3
      Ortiz Ortiz 12 hours ago
      All we need is one approval and is on like DK.
      👍️ 5
      Investor2014 Investor2014 12 hours ago
      It is only 29 times current value. Can anyone see a problem with that?
      👎️ 1 👺 1
      kund kund 13 hours ago
      The market cap is $700 million—who would pay $20 billion when the company can be bought for under a billion? The kick-the-can strategist is focused on maximizing his return and isn't in a hurry to get the drug to market. The EMA filing is just another gimmick from him, knowing it will take years to get any decision from the EMA.
      👍️ 1 👎️ 1 👺 1
      rx7171 rx7171 13 hours ago
      Way low particularly taking into account they also have a credible shot at a number of additional very high value target diseases.
      🎯 3 👍️ 12 😇 1
      Ortiz Ortiz 14 hours ago
      G, I believe a 20 billion buyout is not out of the question. However, I also think that 20b is a low ball offer for Anavex. 
      🎯 3 👍️ 12
      tredenwater2 tredenwater2 17 hours ago
      Like clockwork the nearly daily downturn in the stock price of AVXL is nearly complete at about 3:00 PM EST.

      This very well could of been the case with our PPS even with an announcement of EMA acceptance of our MAA application. If you believe anything else your just fooling yourself, maybe 1 or 2 others, and setting up many for disappointment. Is that your goal, reverse psychology on new longs to drive them crazy thus selling and leaving from daily undiverable expectations unmet ?
      👍️ 2 👺 1 💯 1 ❌️ 1
      Investor2014 Investor2014 18 hours ago
      Looks like you once again got it wrong!!!
      👺 1 ❌️ 1
      123tom 123tom 18 hours ago
      If we look at simple chart picture of a range pattern, from 7.30 bottom zone to 10.30 top zone, in the middle is 8.80 balance.8.75 resistance capped today, and also using slightly different price steps, 7.50 to the resistance shoulder zone 9.50 area, the balance middle is right here around 8.50.... the price action is ending the week settled in this neutral middle zone waiting for next week. The down move set up now is a 1 dollar wave downward to target 7.70 area/ 7.60 ...IF
      It falls down next week. But if it jumps instead in a rally from here.... 1 dollar, back to retest the 9.60 and maybe 10.30, a 2 dollar move from 8.30.
      If good news is the trigger, it would begin the new cycle upward... and I'd be looking first at targets like 12/13/14/15 automatic, before dreaming of any higher, like the 20's.
      But for next week, simply looking for the next 1 dollar movement. 7.65 or 9.65 🎱🫣
      👍️ 4
      georgejjl georgejjl 18 hours ago
      Like clockwork the nearly daily downturn in the stock price of AVXL is nearly complete at about 3:00 PM EST. Do NOT allow the bashers, FUDsters and/or shorters paint the tape prior to the close; make them pay UP; start the SHORT SQEEZE today prior to Monday’s NEWS!!!

      Good luck and GOD bless and have a very merry CHRISTmas!!!
      👍️0
      mike_dotcom mike_dotcom 19 hours ago
      SAVA is outperforming this dogschitt today. One thing is certain - the shorts are very confident that there will be no news of consequence on Monday. Deep down I think most longs know that too.
      😦 1
      kund kund 19 hours ago
      With all the PR since mid 2024, there is still no real progress with this POS. Misleading still milking 2 year old data. He might be getting his new option grants for another unsuccessful year.
      👎️ 1 👺 1
      BDR10 BDR10 19 hours ago
      I have to admit I'm somewhat disappointed in today's stock price I mean the xbi is up nicely and the markets are flying and here we sit dealing with pennies I was hoping to see a lot more today especially with the anticipation that some have for Monday
      👍️ 2
      Investor2014 Investor2014 19 hours ago
      It might well be. Only time will tell.
      👍️ 1 👎️ 1 👺 1
      sumbuysumsell sumbuysumsell 19 hours ago
      Is this not going to be Feb'ish?
      👍️0
      k9uwa k9uwa 19 hours ago
      Stink Bid time. got few at 8.33 SOLD at 8.70. Put in new stink bid.

      John k9uwa
      👍️ 1 👎️ 1
      Investor2014 Investor2014 19 hours ago
      Just FYI. as image that others have done detective work on.
      👍 4
      Steady_T Steady_T 19 hours ago
      That is a reasonable approach. Less risk/less reward.

      If history is a guide there will be a big move up on approval and then a beat down by the mysterious forces on the market.
      There may not be a beat down if approval is followed up by additional news.

      I certainly thought that Rett was going to be approved and we saw how that turned out. My opinion is that AD will be approved. See the previous sentence.
      👍️ 2
      Hosai Hosai 20 hours ago
      It might have taken an incorrect figure, I don't think there is an IF calculated yet for 2024.
      👍️ 2
      Hoskuld Hoskuld 20 hours ago
      I asked google "JPAD 2024 impact factor"
      👍️ 2
      boi568 boi568 20 hours ago
      Authoritarian personality types legitimately cannot handle uncertainty, and that's reflected in some posts. It really stresses them.
      👍️ 4
      mike_dotcom mike_dotcom 20 hours ago
      He's a BIO checker that, for the last 7 years, has ONLY been concerned with ONE bio - Anavex.
      👍️ 3
      Investor2014 Investor2014 20 hours ago
      Well maybe you could explain the thinking behind BIOChecker and what's the with "4". I assume you consider some reference standard for the checking you do of things bio?
      👎️ 1 👺 1
      tredenwater2 tredenwater2 20 hours ago
      Regardless of which journal prints the paper, one thing is that reviewing and writing a peer reviewed paper for the next safe and effective SOC for Alzheimer’s will definitely give that journal a serious “bump”, imo.
      👍️ 13
      tredenwater2 tredenwater2 20 hours ago
      Well said. The tactics deployed through the super complicated programming of algorithms assisted by AI is mind boggling. We see just “the tip of the iceberg” of what is being applied.

      I rely on HIS time, not mine.
      👍️ 4
      BIOChecker4 BIOChecker4 20 hours ago
      Your screen name is investor2014. Why don’t you explain why you chose “investor” instead of daytrader2014 or speculator2014?
      👋 1 👍️ 1
      tredenwater2 tredenwater2 20 hours ago
      Or ppl would just wait till early Jan when most late Dec EMA start dates (which avxl would be) are Pr'ed?


      NOOoo, not ME! Ive waited too long and if its not announced by, by,…..by today dammit I will find the tallest building, light my hair on fire, run and jump off! (Sarc)

      Why are so many continuing to hyperventilate over the stock price at every event or non event. We are very close, I really dont understand it and feel it is unnecessary self gratification by worry warts. Just the opposite of “NEWS TOMORROW!”. May one is feeding the other?

      #Cutthemanicfoodsupply

      Merry Christmas
      👍️ 3
      BIOChecker4 BIOChecker4 20 hours ago
      I look at various situations and state my opinions based on my experience, observations, and intuition. I’m quite prepared to be wrong but so far all the evidence I’ve seen leads me to remain skeptical. I was wrong about Anavex not filing the EMA this year and as you know I offered my congratulations on that accomplishment.

      I’m sorry if not bowing to the approved WGT narrative irritates you but that’s your problem, not mine. Like I’ve said, I’ll gladly pay up if blarcamesine gets approved.
      👎️ 2 👺 2
      Hosai Hosai 20 hours ago
      "2024 impact factor for JPAD is 9.2 - that is very good."

      Interesting, where did you find that? I think 8.6 is the latest IF that is known according to the journal website.

      It seems like JPAD has been increasing each year whereas 'AD & Dementia' falling slightly and 'Journal of AD' not moved much.
      👍️ 7
      Investor2014 Investor2014 20 hours ago
      How do you define "versus actual investors"?
      👎️ 1 👺 1
      Hoskuld Hoskuld 20 hours ago
      Supposedly, 2024 impact factor for JPAD is 9.2 - that is very good.
      👍️ 10
      BIOChecker4 BIOChecker4 21 hours ago
      The only thing I’m convinced of is that the outcome is unknowable. That’s why I’ll be perfectly happy to pay up on approval, should it happen. Unless and until that happens, AVXL remains a speculative play with significant risks better suited to speculators and day traders versus actual investors.
      👎️ 1 👺 1
      sab63090 sab63090 21 hours ago
      Many here are focusing on Monday's expected news....
      which sets you up for disappointment and you can be sure the mm's and robot trading systems will hop on the lack of it! We certainly are trading quietly yet under a potential strong inflection point, too. The triangle is still there with a very minor uptrend also holding up...the flat top horizontal level is $10.50, so it will require a heated rally to bust out and make some short sellers report back to their chief trader on how to handle....or....for me to step back from my very bullish outlook. I think I have the odds in my favor, but we'll see how $AVXL handles any lack of news or responds to strong buying. We leave tomorrow for Christmas week very early....Merry Christmas! 🤩
      👍️ 6
      mike_dotcom mike_dotcom 21 hours ago
      Feb. It's always Feb.
      👍️ 1
      Hosai Hosai 21 hours ago
      "if it is not announced, the stock will tank."

      Or ppl would just wait till early Jan when most late Dec EMA start dates (which avxl would be) are Pr'ed?
      👍️ 5
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 21 hours ago
      The current triangle we see "ought to" break upward,

      Sure looks like it wants to, with considerable momentum. But I wouldn't credit manipulators either way, it is building on an expectation of an EMA acceptance of application being announced on Monday, if it is not announced, the stock will tank.

      Current melting due to lack of EMA announcement already.
      👋 1 👍️ 3 🫡 1
      Investor2014 Investor2014 22 hours ago
      Glacial pace picking up speed thanks to global warming and hope Dr. Missling feels it under his feet too.
      👍️ 2 👎️ 2 👺 1 😋 2
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 22 hours ago
      Money is continuing to change hands over Alzheimer's drug candidates. The example given was still of the old amyloid MAB type, guess they dont learn.

      There is no question that Anavex is talking to BPhama suitors! Maybe, or not. Been saying that for years....the old girl is getting grey with no offers of courtship, let alone marriage. Either she is Christmas cake or Elizabeth I.

      "With recent approvals in the space, the Alzheimer’s market is projected to rapidly expand with some forecasts reaching $15.5 billion by 2031." by far the most useful sentence in the story.
      🎯 1 👍️ 3
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 22 hours ago
      I was wondering the same thing. Is this even about Anavex??
      “10 biotech companies to watch in 2025" December 16, 2024

      The material came from some others in the 10 Companies list. The point was how many competitors are exploring similar pathways of efficacy. Good in that it verifies the pathways, bad in that is shows how much competition AVXL will have and how the glacial pace it has moved threatens to make it a laggard instead of a leader.
      👍️ 1

      Your Recent History

      NASDAQ
      AVXL
      Anavex Life Sciences
      LSE
      80AT
      Perm Mast 58 A
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads